Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyOscar Health Microorganism Test Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedOscar HealthPolicy N/A

    Identification of Microorganisms using Nucleic Acid Probes

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria for individual direct-probe, amplified-probe, and quantification nucleic acid tests used to identify microorganisms, subject to benefit, medical necessity, authorization, state, and coding requirements.

    Policy Summary
    PayerOscar Health
    PolicyIdentification of Microorganisms using Nucleic Acid Probes
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 28, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation of services performed and code claims according to applicable billing guidelines.
    SourceLink
    POLICY UPDATE CHANGES

    The policy update added CPT codes 87594 and 87638 to the Applicable CPT/HCPCS Procedure Codes section.

    The policy background, guidelines, and evidence-based scientific references were updated.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2CPT codes added
    20Microorganism/test targets in coverage table
    MCTests meeting criteria
    DNMCTests not meeting criteria
    1Excluded same-organism ordering combination

    Coverage Criteria

    Procedure-Specific Microorganism Testing Criteria

    For the requested microorganism and procedure, apply the coverage designation shown below. “MC” means the test meets criteria; “DNMC” means the test does not meet criteria. A procedure marked “not listed” has no corresponding code shown in the coverage table.

    ONE microorganism/procedure combination

    • Bartonella henselae

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87471 — MC (meets criteria).
      • Quantification: CPT 87472 — DNMC (does not meet criteria).
    • Chlamydia pneumoniae

      • Direct probe: CPT 87485 — DNMC (does not meet criteria).
      • Amplified probe: CPT 87486 — MC (meets criteria).
      • Quantification: CPT 87487 — DNMC (does not meet criteria).
    • Clostridium difficile

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87493 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Cytomegalovirus

      • Direct probe: CPT 87495 — DNMC (does not meet criteria).
      • Amplified probe: CPT 87496 — MC (meets criteria).
      • Quantification: CPT 87497 — MC (meets criteria).
    • Enterococcus, vancomycin-resistant (e.g., enterococcus vanA, vanB)

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87500 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Enterovirus

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87498 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Hepatitis G

      • Direct probe: CPT 87525 — DNMC (does not meet criteria).
      • Amplified probe: CPT 87526 — DNMC (does not meet criteria).
      • Quantification: CPT 87527 — DNMC (does not meet criteria).
    • Herpes virus-6

      • Direct probe: CPT 87531 — DNMC (does not meet criteria).
      • Amplified probe: CPT 87532 — DNMC (does not meet criteria).
      • Quantification: CPT 87533 — MC (meets criteria).
    • Legionella pneumophila

      • Direct probe: CPT 87540 — DNMC (does not meet criteria).
      • Amplified probe: CPT 87541 — MC (meets criteria).
      • Quantification: CPT 87542 — DNMC (does not meet criteria).
    • Orthopoxvirus

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87593 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Pneumocystis jirovecii

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87594 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Mycoplasma pneumoniae

      • Direct probe: CPT 87580 — DNMC (does not meet criteria).
      • Amplified probe: CPT 87581 — MC (meets criteria).
      • Quantification: CPT 87582 — DNMC (does not meet criteria).
    • Respiratory syncytial virus

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87634 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Rubeola virus

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87638 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Staphylococcus aureus

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87640 — MC (meets criteria).
      • Quantification: not listed in the coverage table.
    • Staphylococcus aureus, methicillin

      • Direct probe: not listed in the coverage table.
      • Amplified probe: CPT 87641 — MC (meets criteria).
      • Quantification: the source table excerpt does not specify a code or designation.

    Simultaneous Amplified Probe and Quantification

    The following ordering combination does not meet criteria.

    Amplified probe and quantification ordered simultaneously for the same organism during a single encounter does not meet criteria.

    Table 1 summarizes whether nucleic acid identification testing using direct probe, amplified probe, or quantification procedure codes meets criteria. “MC” indicates that the test meets criteria, and “DNMC” indicates that the test does not meet criteria.

    Simultaneous ordering of amplified probe and quantification for the same organism in a single encounter does not meet criteria.

    Applicable Codes and Coding Rules

    CPT codes designated MC (meets criteria)CPTCovered
    87471Bartonella henselae — amplified probe
    87486Chlamydia pneumoniae — amplified probe
    87493Clostridium difficile — amplified probe
    87496Cytomegalovirus — amplified probe
    87497Cytomegalovirus — quantification
    87500Vancomycin-resistant Enterococcus, including enterococcus vanA or vanB — amplified probe
    87498Enterovirus — amplified probe
    87533Herpes virus-6 — quantification
    87541Legionella pneumophila — amplified probe
    87593Orthopoxvirus — amplified probe
    1–10 of 16
    1/2
    CPT codes designated DNMC (does not meet criteria)CPTNot Covered
    87472Bartonella henselae — quantification
    87485Chlamydia pneumoniae — direct probe
    87487Chlamydia pneumoniae — quantification
    87495Cytomegalovirus — direct probe
    87525Hepatitis G — direct probe
    87526Hepatitis G — amplified probe
    87527Hepatitis G — quantification
    87531Herpes virus-6 — direct probe
    87532Herpes virus-6 — amplified probe
    87540Legionella pneumophila — direct probe
    1–10 of 13
    1/2
    Applicable CPT/HCPCS Procedure CodesCPT
    87471Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique
    87472Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, quantification
    87485Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique
    87486Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique
    87487Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification
    87493Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique
    87495Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique
    87496Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, amplified probe technique
    87497Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification
    87498Infectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed
    1–10 of 20
    1/2
    Applicable CPT/HCPCS Procedure CodesCPTCovered
    87594Infectious agent detection by nucleic acid (DNA or RNA); Pneumocystis jirovecii, amplified probe technique
    87638Infectious agent detection by nucleic acid (DNA or RNA); rubeola (measles) virus
    HHV-6 quantitative PCR
    TestHHV-6 quantitative PCR
    Active infection threshold>200 copies per mL of blood
    Alternative threshold20 copies per microgram of DNA

    Provider and Billing Actions

    Documentation Required

    Submit Accurate Service Documentation

    Providers are responsible for submitting accurate documentation of the services performed and coding claims appropriately under applicable industry-standard coding guidelines.

    Documentation Required

    Document PJP Testing Indications

    For PJP testing, the requisition must document that the patient is immunocompromised, has relevant risk factors, and has clinical symptoms suggestive of PJP infection.

    • Include the required immunocompromised status, risk factors, and symptoms on the requisition.
    • Only one specimen per patient per week will be tested; pooled specimens are accepted.

    Covered Testing Indications

    Individual Nucleic Acid Probe Testing

    Individual nucleic acid probe testing is covered for the following organisms when the specific procedure is designated MC in the coverage table.

    Covered organism and procedure designation: The requested individual nucleic acid probe test targets Bartonella henselae, Chlamydia pneumoniae, Clostridium difficile, cytomegalovirus, vancomycin-resistant Enterococcus, Enterovirus, Herpes virus-6, Legionella pneumophila, Orthopoxvirus, Pneumocystis jirovecii, Mycoplasma pneumoniae, respiratory syncytial virus, Rubeola virus, Staphylococcus aureus, or methicillin-resistant Staphylococcus aureus.

    The specific direct-probe, amplified-probe, or quantification procedure must be designated MC in the coverage table. Covered examples include amplified probe testing for Bartonella henselae, Chlamydia pneumoniae, Clostridium difficile, cytomegalovirus, vancomycin-resistant Enterococcus, Enterovirus, Legionella pneumophila, Orthopoxvirus, Pneumocystis jirovecii, Mycoplasma pneumoniae, respiratory syncytial virus, Rubeola virus, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus; quantification testing for cytomegalovirus and Herpes virus-6; and no other procedure category unless designated MC.

    Mycoplasma pneumoniae Infection

    Covered for diagnosis of Mycoplasma pneumoniae infection when molecular testing is clinically indicated.

    Mycoplasma pneumoniae diagnostic testing

    Testing Frequency and Specimen Limits

    Pneumocystis jirovecii testing
    Testing limitOnly one specimen per patient will be tested
    Testing periodPer week
    Pooled specimensPooled specimens will be accepted
    Mpox virus testing
    Post-recovery timingFollowing the initial 12 weeks and up to 6 months after recovery from infection
    Primary specimenSemen samples
    Additional specimens when necessaryOropharyngeal and/or rectal swabs

    Ordering Requirements

    Documentation Required

    Follow specimen-ordering requirements

    Include the required clinical information and collect the specified specimen for the test being ordered. For PJP testing, the requisition must document immunocompromised status, relevant risk factors, and clinical symptoms suggestive of infection; for mpox lesion testing, collect a viral swab from an open sore, vesicle, ulcer, or crusted vesicle, with an additional throat swab when pharyngeal lesions are present.

    • PJP requisition: document immunocompromised status, relevant risk factors, and suggestive clinical symptoms.
    • Mpox lesion testing: collect a viral swab from an open sore, vesicle, ulcer, or crusted vesicle.
    • Collect an additional throat swab when pharyngeal lesions are present.

    Not Covered Services

    Procedures designated DNMC in the policy table do not meet criteria. In addition, simultaneous amplified probe and quantification testing for the same organism in a single encounter does not meet criteria, regardless of the individual procedure designations. This policy addresses individual nucleic acid probe tests; multiplex panels are outside its scope.

    Background

    Nucleic acid hybridization and amplification methods are used to detect pathogens in blood cultures and other clinical specimens. These methods include polymerase chain reaction (PCR), ligase- or helicase-dependent amplification, and transcription-mediated amplification. Compared with traditional microbiologic methods, they may provide greater sensitivity and specificity, faster results, and higher throughput. Limitations include contamination, assay standardization or validation issues, complex result interpretation, and increased cost. This policy evaluates individual microorganism probes rather than multiplex panels.

    Definitions and Abbreviations

    DNMC
    AbbreviationDNMC
    Expanded termDoes not meet criteria
    Policy meaningThe procedure does not meet criteria
    MC
    AbbreviationMC
    Expanded termMeets criteria
    Policy meaningThe procedure meets criteria
    Policy Summary
    PayerOscar Health
    PolicyIdentification of Microorganisms using Nucleic Acid Probes
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 28, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation of services performed and code claims according to applicable billing guidelines.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Codes and Coding RulesProvider and Billing ActionsCovered Testing IndicationsTesting Frequency and Specimen LimitsOrdering RequirementsNot Covered ServicesBackgroundDefinitions and Abbreviations
    Billing Rule

    Do Not Combine Amplified Probe and Quantification Testing

    Do not simultaneously order amplified probe and quantification testing for the same organism during a single encounter; this combination does not meet coverage criteria.

    Denial Risk

    Inaccurate Coding or Documentation Risks Denial

    Failure to follow applicable coding, billing, or current reimbursement policies may result in claim denial and/or recoupment of claim payment.

    Note

    Meet Benefit and Medical Necessity Requirements

    Coverage determinations depend on the member’s benefit coverage at the time of the request, and the service must meet applicable authorization and medical necessity requirements for the procedure, diagnosis, and member’s state of residence.

    • Coverage does not guarantee reimbursement.
    • Other benefit documents, provider contracts, legislative mandates, and related reimbursement policies may modify or supersede these requirements.
    Documentation Required

    Complete PJP Clinical Information

    Incomplete clinical information on the PJP requisition can result in rejection of the specimen for testing.

    • Document immunocompromised status, risk factors, and clinical symptoms suggestive of PJP infection.
    • Only one specimen per patient per week will be tested; pooled specimens are accepted.
    Denial Risk

    Use an Acceptable PJP Specimen

    Submit an acceptable specimen type for PJP testing; swab and expectorated sputum specimens are not acceptable.

    • Specimens collected using swabs will be rejected.
    • Expectorated sputum specimens will be rejected.
    • Pooled specimens are accepted.
    • Use a nucleic acid amplification test (NAAT) for diagnosis.

      NAATs are identified as the preferred diagnostic method because they offer high sensitivity and specificity, provide timely results for treatment decisions, and may predict antibiotic susceptibilities.

    Respiratory Syncytial Virus Infection

    Covered for diagnosis of respiratory syncytial virus infection when molecular testing is clinically indicated.

    RSV diagnostic testing

    • Use a nucleic acid amplification test, such as PCR.

      NAATs such as PCR are highly sensitive and can be used to diagnose anyone with RSV.

    Probable or Suspected Mpox

    Covered for probable or suspected mpox when testing follows an appropriate molecular testing pathway.

    Probable or suspected mpox

    • ONE of

      • Perform mpox-virus-specific PCR and confirm the result through sequencing.
      • Perform orthopoxvirus-specific PCR and confirm the result through sequencing.
      • For a lesion-based evaluation, collect a viral swab from an open sore, vesicle, ulcer, or crusted vesicle for PCR.

        If pharyngeal lesions are present, collect a throat swab as well.

      • For a high-risk contact with systemic symptoms but no rash or lesion available for sampling, a viral throat swab may be collected.

    Pneumocystis jirovecii Pneumonia

    Covered when the patient has clinical features and risk factors suggestive of Pneumocystis jirovecii pneumonia and an acceptable respiratory specimen is submitted.

    Pneumocystis jirovecii pneumonia testing

    • The patient is immunocompromised, has relevant risk factors, and has clinical symptoms suggestive of Pneumocystis jirovecii pneumonia.

      This information must be documented on the testing requisition.

    • ONE of

      • Test an induced sputum specimen by PCR.
      • Test a bronchoalveolar lavage specimen by PCR.
    • The specimen is not collected by swab and is not expectorated sputum.

      Only one specimen per patient per week will be tested.

    • When a definitive diagnosis is required, demonstration of the organism by histopathology or cytopathology in tissue, bronchoalveolar lavage fluid, or induced sputum supports diagnosis.

    Methicillin-Resistant Staphylococcus aureus

    Covered for methicillin-resistant Staphylococcus aureus testing when molecular detection of oxacillin resistance is clinically indicated.

    MRSA molecular testing: The requested PCR test is used to detect the mecA gene, which mediates oxacillin resistance in staphylococci.

    mecA PCR does not detect novel resistance mechanisms or uncommon phenotypes, including mecC or borderline-resistant oxacillin resistance; those limitations must be considered when interpreting the result.

    NAAT
    AbbreviationNAAT
    Expanded termNucleic acid amplification test
    Test categoryA test that amplifies nucleic acid for detection
    PCR
    AbbreviationPCR
    Expanded termPolymerase chain reaction
    Method categoryA nucleic acid amplification method
    qPCR
    AbbreviationqPCR
    Expanded termQuantitative polymerase chain reaction
    Method categoryA quantitative polymerase chain reaction method
    FRET
    AbbreviationFRET
    Expanded termFluorescent resonance energy transfer
    Term categoryA fluorescence-based energy transfer term
    CIDT
    AbbreviationCIDT
    Expanded termCulture-independent diagnostic test
    Test categoryA diagnostic test that is independent of culture
    CMV
    AbbreviationCMV
    Expanded termCytomegalovirus
    Term categoryA virus name
    MRSA
    AbbreviationMRSA
    Expanded termMethicillin-resistant Staphylococcus aureus
    Term categoryA methicillin-resistant bacterial species designation